MoonLake Immunotherapeutics MLTX
NASDAQ MLTX
$11.79 +0.34 (+2.97%)
As of: Sep 30, 2026 · 12:24 PM EDT

MoonLake Immunotherapeutics (MLTX) EBIT (2021 - 2026)

Updated

MoonLake Immunotherapeutics (MLTX) posted EBIT of -$61.66 million for Q2 2026, compared with -$60.7 million a year earlier.

Analysis

MoonLake Immunotherapeutics (MLTX) EBIT (2021 - 2026) Analysis & Trends

For the trailing twelve months through Jun 30, 2026, EBIT at MoonLake Immunotherapeutics was -$268.34 million; for FY2025, it was -$244.83 million.

  • In prior years, MoonLake Immunotherapeutics' EBIT was -$143.09 million in FY2024, -$54.12 million in FY2023, -$65.06 million in FY2022 and -$53.58 million in FY2021.
  • Quarterly EBIT has run from a low of -$71.43 million in Q3 2025 to a high of -$6.27 million in Q3 2021 over five years.
  • According to Business Quant data, EBIT for the three prior quarters was -$70.02 million (Q1 2026), -$65.22 million (Q4 2025) and -$71.43 million (Q3 2025).
Peer Set

Peer Comparison

Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -61.66 Mn
Mar 31, 2026 -70.02 Mn
Dec 31, 2025 -65.22 Mn
Sep 30, 2025 -71.43 Mn
Jun 30, 2025 -60.70 Mn
Mar 31, 2025 -47.49 Mn
Dec 31, 2024 -49.58 Mn
Sep 30, 2024 -43.11 Mn
Jun 30, 2024 -30.58 Mn
Mar 31, 2024 -19.82 Mn
Dec 31, 2023 -15.03 Mn
Sep 30, 2023 -12.98 Mn
Jun 30, 2023 -13.19 Mn
Mar 31, 2023 -12.93 Mn
Dec 31, 2022 -16.70 Mn
Sep 30, 2022 -14.77 Mn
Jun 30, 2022 -17.65 Mn
Mar 31, 2022 -15.94 Mn
Dec 31, 2021 -14.28 Mn
Sep 30, 2021 -6.27 Mn
API Access

MoonLake Immunotherapeutics EBIT API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=ebit&ticker=MLTX&period=max&api_key=YOUR_API_KEY